All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy

Journal of the American College of Cardiology

Volumn 61, Issue 9, 2013, Pages 948-954

  Schram, Gernot ^a   Fournier, Anne ^b   Leduc, Hugues ^a   Dahdah, Nagib ^b   Therien, Johanne ^b   Vanasse, Michel ^b   Khairy, Paul ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITY OF MONTREAL   (Canada)

Author keywords

cardiomyopathy; Duchenne muscular dystrophy; mortality; steroids

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DEFLAZACORT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; PREDNISONE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM ANTAGONIST; RENIN INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CARDIOMYOPATHY; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DUCHENNE MUSCULAR DYSTROPHY; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; SCHOOL CHILD;

CARDIOMYOPATHIES; CARDIOVASCULAR DISEASES; CHILD; COHORT STUDIES; HEART FAILURE; HUMANS; MALE; MULTIVARIATE ANALYSIS; MUSCULAR DYSTROPHY, DUCHENNE; RENIN-ANGIOTENSIN SYSTEM; STEROIDS; STROKE VOLUME; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84875444308     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.12.008     Document Type: Article

References (35)

1. M. Eagle, S.V. Baudouin, C. Chandler, D.R. Giddings, R. Bullock, K. Bushby Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation Neuromuscul Disord 12 2002 926 929
2. W.D. Biggar, V.A. Harris, L. Eliasoph, B. Alman Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade Neuromuscul Disord 16 2006 249 255
3. K. Bushby, R. Finkel, D.J. Birnkrant Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management Lancet Neurol 9 2010 77 93
4. J. Gilroy, J.L. Cahalan, R. Berman, M. Newman Cardiac and pulmonary complications in Duchenne's progressive muscular dystrophy Circulation 27 1963 484 493
5. P. Melacini, A. Vianello, C. Villanova Cardiac and respiratory involvement in advanced stage Duchenne muscular dystrophy Neuromuscul Disord 6 1996 367 376
6. B.J. Petrof, J.B. Shrager, H.H. Stedman, A.M. Kelly, H.L. Sweeney Dystrophin protects the sarcolemma from stresses developed during muscle contraction Proc Natl Acad Sci U S A 90 1993 3710 3714
7. M. Sandri, M. Podhorska-Okolow, V. Geromel Exercise induces myonuclear ubiquitination and apoptosis in dystrophin-deficient muscle of mice J Neuropathol Exp Neurol 56 1997 45 57
8. T.N. James Observations on the cardiovascular involvement, including the cardiac conduction system, in progressive muscular dystrophy Am Heart J 63 1962 48 56
9. K.A. Frankel, R.J. Rosser The pathology of the heart in progressive muscular dystrophy: epimyocardial fibrosis Hum Pathol 7 1976 375 386
10. K. Ueda, R. Okada, H. Matsuo, K. Harumi, H. Yasuda Myocardial involvement in benign Duckenne type of progressive muscular dystrophy Jpn Heart J 11 1970 26 35
11. D. Duboc, C. Meune, B. Pierre Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up Am Heart J 154 2007 596 602
12. G. Corrado, A. Lissoni, S. Beretta Prognostic value of electrocardiograms, ventricular late potentials, ventricular arrhythmias, and left ventricular systolic dysfunction in patients with Duchenne muscular dystrophy Am J Cardiol 89 2002 838 841
13. M. Burch, S.A. Siddiqi, D.S. Celermajer, C. Scott, C. Bull, J.E. Deanfield Dilated cardiomyopathy in children: determinants of outcome Br Heart J 72 1994 246 250
14. G. Nigro, L.I. Comi, L. Politano, R.J. Bain The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy Int J Cardiol 26 1990 271 277
15. J.M. de Kermadec, H.M. Becane, A. Chenard, F. Tertrain, Y. Weiss Prevalence of left ventricular systolic dysfunction in Duchenne muscular dystrophy: an echocardiographic study Am Heart J 127 1994 618 623
16. A. Fayssoil, O. Nardi, D. Orlikowski, D. Annane Cardiomyopathy in Duchenne muscular dystrophy: pathogenesis and therapeutics Heart Fail Rev 15 2010 103 107
17. D. Duboc, C. Meune, G. Lerebours, J.Y. Devaux, G. Vaksmann, H.M. Becane Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy J Am Coll Cardiol 45 2005 855 857
18. J.L. Jefferies, B.W. Eidem, J.W. Belmont Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy Circulation 112 2005 2799 2804
19. S. Houde, M. Filiatrault, A. Fournier Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up Pediatr Neurol 38 2008 200 206
20. A.Y. Manzur, T. Kuntzer, M. Pike, A. Swan Glucocorticoid corticosteroids for Duchenne muscular dystrophy Cochrane Database Syst Rev 2008 CD003725
21. S.D. Solomon, D. Wang, P. Finn Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program Circulation 110 2004 2180 2183
22. G.B. Haycock, G.J. Schwartz, D.H. Wisotsky Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults J Pediatr 93 1978 62 66
23. R.M. Lang, M. Bierig, R.B. Devereux Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology J Am Soc Echocardiogr 18 2005 1440 1463
24. M. Wehling-Henricks, M.C. Jordan, K.P. Roos, B. Deng, J.G. Tidball Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium Hum Mol Gen 14 2005 1921 1933
25. N.P. Whitehead, E.W. Yeung, D.G. Allen Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species Clin Exp Pharmacol Physiol 33 2006 657 662
26. I.A. Williams, D.G. Allen Intracellular calcium handling in ventricular myocytes from mdx mice Am J Physiol Heart Circ Physiol 292 2007 H846 H855
27. K.M. English, J.L. Gibbs Cardiac monitoring and treatment for children and adolescents with neuromuscular disorders Dev Med Child Neurol 48 2006 231 235
28. American Academy of Pediatrics Section on Cardiology and Cardiac Surgery Cardiovascular health supervision for individuals affected by Duchenne or Becker muscular dystrophy Pediatrics 116 2005 1569 1573
29. V. Giglio, V. Pasceri, L. Messano Ultrasound tissue characterization detects preclinical myocardial structural changes in children affected by Duchenne muscular dystrophy J Am Coll Cardiol 42 2003 309 316
30. K. Sasaki, K. Sakata, E. Kachi, S. Hirata, T. Ishihara, K. Ishikawa Sequential changes in cardiac structure and function in patients with Duchenne type muscular dystrophy: a two-dimensional echocardiographic study Am Heart J 135 1998 937 944
31. G. Nigro, L.I. Comi, L. Politano, V. Nigro Dilated cardiomyopathy of muscular dystrophy: a multifaceted approach to management Semin Neurol 15 1995 90 92
32. S.D. Colan Evolving therapeutic strategies for dystrophinopathies: potential for conflict between cardiac and skeletal needs Circulation 112 2005 2756 2758
33. L.W. Markham, R.L. Spicer, P.R. Khoury, B.L. Wong, K.D. Mathews, L.H. Cripe Steroid therapy and cardiac function in Duchenne muscular dystrophy Pediatr Cardiol 26 2005 768 771
34. L.W. Markham, K. Kinnett, B.L. Wong, D. Woodrow Benson, L.H. Cripe Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy Neuromuscul Disord 18 2008 365 370
35. C.K. Silversides, G.D. Webb, V.A. Harris, D.W. Biggar Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy Am J Cardiol 91 2003 769 772